IL-7R-mediated signaling in T-cell acute lymphoblastic leukemia

Advances in Biological Regulation

Volumn 53, Issue 2, 2013, Pages 211-222

  Ribeiro, Daniel ^a   Melão, Alice ^a   Barata, João T ^a  

^a INSTITUTO DE MEDICINA MOLECULAR JOÃO LOBO ANTUNES   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84878596429     PISSN: 22124926     EISSN: None     Source Type: Book Series    
DOI: 10.1016/j.jbior.2012.10.005     Document Type: Review

References (124)

1. Abraham N., Ma M.C., Snow J.W., Miners M.J., Herndier B.G., Goldsmith M.A. Haploinsufficiency identifies STAT5 as a modifier of IL-7-induced lymphomas. Oncogene 2005, 24:5252-5257.
2. Al-Rawi M.A., Mansel R.E., Jiang W.G. Interleukin-7 (IL-7) and IL-7 receptor (IL-7R) signalling complex in human solid tumours. Histol Histopathol 2003, 18:911-923.
3. Al-Rawi M.A., Rmali K., Watkins G., Mansel R.E., Jiang W.G. Aberrant expression of interleukin-7 (IL-7) and its signalling complex in human breast cancer. Eur J Cancer 2004, 40:494-502.
4. Alves N.L., Richard-Le Goff O., Huntington N.D., Sousa A.P., Ribeiro V.S., Bordack A., et al. Characterization of the thymic IL-7 niche in vivo. Proc Natl Acad Sci U S A 2009, 106:1512-1517.
5. Azevedo R.I., Soares M.V., Barata J.T., Tendeiro R., Serra-Caetano A., Victorino R.M., et al. IL-7 sustains CD31 expression in human naive CD4+ T cells and preferentially expands the CD31+ subset in a PI3K-dependent manner. Blood 2009, 113:2999-3007.
6. Bains T., Heinrich M.C., Loriaux M.M., Beadling C., Nelson D., Warrick A., et al. Newly described activating JAK3 mutations in T-cell acute lymphoblastic leukemia. Leukemia 2012, 26:2144-2146.
7. Balciunaite G., Ceredig R., Fehling H.J., Zuniga-Pflucker J.C., Rolink A.G. The role of Notch and IL-7 signaling in early thymocyte proliferation and differentiation. Eur J Immunol 2005, 35:1292-1300.
8. Barata J.T., Boussiotis V.A., Yunes J.A., Ferrando A.A., Moreau L.A., Veiga J.P., et al. IL-7-dependent human leukemia T-cell line as a valuable tool for drug discovery in T-ALL. Blood 2004, 103:1891-1900.
9. Barata J.T., Cardoso A.A., Boussiotis V.A. Interleukin-7 in T-cell acute lymphoblastic leukemia: an extrinsic factor supporting leukemogenesis?. Leuk Lymphoma 2005, 46:483-495.
10. Barata J.T., Cardoso A.A., Nadler L.M., Boussiotis V.A. Interleukin-7 promotes survival and cell cycle progression of T-cell acute lymphoblastic leukemia cells by down-regulating the cyclin-dependent kinase inhibitor p27(kip1). Blood 2001, 98:1524-1531.
11. Barata J.T., Keenan T.D., Silva A., Nadler L.M., Boussiotis V.A., Cardoso A.A. Common gamma chain-signaling cytokines promote proliferation of T-cell acute lymphoblastic leukemia. Haematologica 2004, 89:1459-1467.
12. Barata J.T., Silva A., Abecasis M., Carlesso N., Cumano A., Cardoso A.A. Molecular and functional evidence for activity of murine IL-7 on human lymphocytes. Exp Hematol 2006, 34:1133-1142.
13. Barata J.T., Silva A., Brandao J.G., Nadler L.M., Cardoso A.A., Boussiotis V.A. Activation of PI3K is indispensable for interleukin 7-mediated viability, proliferation, glucose use, and growth of T cell acute lymphoblastic leukemia cells. J Exp Med 2004, 200:659-669.
14. Batista A., Barata J.T., Raderschall E., Sallan S.E., Carlesso N., Nadler L.M., et al. Targeting of active mTOR inhibits primary leukemia T cells and synergizes with cytotoxic drugs and signaling inhibitors. Exp Hematol 2011, 39:457-472. e3.
15. Boyman O., Ramsey C., Kim D.M., Sprent J., Surh C.D. IL-7/anti-IL-7 mAb complexes restore T cell development and induce homeostatic T cell expansion without lymphopenia. J Immunol 2008, 180:7265-7275.
16. Brown V.I., Fang J., Alcorn K., Barr R., Kim J.M., Wasserman R., et al. Rapamycin is active against B-precursor leukemia in vitro and in vivo, an effect that is modulated by IL-7-mediated signaling. Proc Natl Acad Sci U S A 2003, 100:15113-15118.
17. Buckley R.H. Molecular defects in human severe combined immunodeficiency and approaches to immune reconstitution. Ann Rev Immunol 2004, 22:625-655.
18. Cattaruzza L., Gloghini A., Olivo K., Di Francia R., Lorenzon D., De Filippi R., et al. Functional coexpression of Interleukin (IL)-7 and its receptor (IL-7R) on Hodgkin and Reed-Sternberg cells: involvement of IL-7 in tumor cell growth and microenvironmental interactions of Hodgkin's lymphoma. Int J Cancer 2009, 125:1092-1101.
19. Chiarini F., Grimaldi C., Ricci F., Tazzari P.L., Evangelisti C., Ognibene A., et al. Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against T-cell acute lymphoblastic leukemia. Cancer Res 2010, 70:8097-8107.
20. Chowdhury D., Sen R. Transient IL-7/IL-7R signaling provides a mechanism for feedback inhibition of immunoglobulin heavy chain gene rearrangements. Immunity 2003, 18:229-241.
21. Churchman S.M., Ponchel F. Interleukin-7 in rheumatoid arthritis. Rheumatology (Oxford) 2008, 47:753-759.
22. Cosenza L., Gorgun G., Urbano A., Foss F. Interleukin-7 receptor expression and activation in nonhaematopoietic neoplastic cell lines. Cell Signal 2002, 14:317-325.
23. Digel W., Schmid M., Heil G., Conrad P., Gillis S., Porzsolt F. Human interleukin-7 induces proliferation of neoplastic cells from chronic lymphocytic leukemia and acute leukemias. Blood 1991, 78:753-759.
24. Eder M., Ottmann O.G., Hansen-Hagge T.E., Bartram C.R., Gillis S., Hoelzer D., et al. Effects of recombinant human IL-7 on blast cell proliferation in acute lymphoblastic leukemia. Leukemia 1990, 4:533-540. Official Journal of the Leukemia Society of America, Leukemia Research Fund, UK.
25. Elliott N.E., Cleveland S.M., Grann V., Janik J., Waldmann T.A., Dave U.P. FERM domain mutations induce gain of function in JAK3 in adult T-cell leukemia/lymphoma. Blood 2011, 118:3911-3921.
26. Evangelisti C., Ricci F., Tazzari P., Tabellini G., Battistelli M., Falcieri E., et al. Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemia. Leukemia 2011, 25:781-791. Official Journal of the Leukemia Society of America, Leukemia Research Fund, UK.
27. Flex E., Petrangeli V., Stella L., Chiaretti S., Hornakova T., Knoops L., et al. Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia. J Exp Med 2008, 205:751-758.
28. Foss F.M., Koc Y., Stetler-Stevenson M.A., Nguyen D.T., O'Brien M.C., Turner R., et al. Costimulation of cutaneous T-cell lymphoma cells by interleukin-7 and interleukin-2: potential autocrine or paracrine effectors in the Sezary syndrome. J Clin Oncol 1994, 12:326-335.
29. Fox C.J., Hammerman P.S., Thompson C.B. The Pim kinases control rapamycin-resistant T cell survival and activation. J Exp Med 2005, 201:259-266.
30. Frishman J., Long B., Knospe W., Gregory S., Plate J. Genes for interleukin 7 are transcribed in leukemic cell subsets of individuals with chronic lymphocytic leukemia. J Exp Med 1993, 177:955-964.
31. Fruman D.A., Bismuth G. Fine tuning the immune response with PI3K. Immunol Rev 2009, 228:253-272.
32. Fry T.J., Mackall C.L. Interleukin-7: from bench to clinic. Blood 2002, 99:3892-3904.
33. Fry T.J., Moniuszko M., Creekmore S., Donohue S.J., Douek D.C., Giardina S., et al. IL-7 therapy dramatically alters peripheral T-cell homeostasis in normal and SIV-infected nonhuman primates. Blood 2003, 101:2294-2299.
34. Gonzalez-Garcia S., Garcia-Peydro M., Martin-Gayo E., Ballestar E., Esteller M., Bornstein R., et al. CSL-MAML-dependent Notch1 signaling controls T lineage-specific IL-7R{alpha} gene expression in early human thymopoiesis and leukemia. J Exp Med 2009, 206:779-791.
35. Goodwin R.G., Friend D., Ziegler S.F., Jerzy R., Falk B.A., Gimpel S., et al. Cloning of the human and murine interleukin-7 receptors: demonstration of a soluble form and homology to a new receptor superfamily. Cell 1990, 60:941-951.
36. Grenningloh R., Tai T.S., Frahm N., Hongo T.C., Chicoine A.T., Brander C., et al. Ets-1 maintains IL-7 receptor expression in peripheral T cells. J Immunol 2011, 186:969-976.
37. Grimaldi C., Chiarini F., Tabellini G., Ricci F., Tazzari P.L., Battistelli M., et al. AMP-dependent kinase/mammalian target of rapamycin complex 1 signaling in T-cell acute lymphoblastic leukemia: therapeutic implications. Leukemia 2012, 26:91-100. Official Journal of the Leukemia Society of America, Leukemia Research Fund, UK.
38. Guimond M., Veenstra R.G., Grindler D.J., Zhang H., Cui Y., Murphy R.D., et al. Interleukin 7 signaling in dendritic cells regulates the homeostatic proliferation and niche size of CD4+ T cells. Nat Immunol 2009, 10:149-157.
39. Gutierrez A., Sanda T., Grebliunaite R., Carracedo A., Salmena L., Ahn Y., et al. High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia. Blood 2009, 114:647-650.
40. Hara T., Shitara S., Imai K., Miyachi H., Kitano S., Yao H., et al. Identification of IL-7-Producing Cells in Primary and Secondary Lymphoid Organs Using IL-7-GFP Knock-In Mice. J Immunol 2012, 189:1577-1584.
41. Henriques C.M., Rino J., Nibbs R.J., Graham G.J., Barata J.T. IL-7 induces rapid clathrin-mediated internalization and JAK3-dependent degradation of IL-7Ralpha in T cells. Blood 2010, 115:3269-3277.
42. Jeong E.G., Kim M.S., Nam H.K., Min C.K., Lee S., Chung Y.J., et al. Somatic mutations of JAK1 and JAK3 in acute leukemias and solid cancers. Clin Cancer Res 2008, 14:3716-3721.
43. Jiang Q., Li W.Q., Aiello F.B., Mazzucchelli R., Asefa B., Khaled A.R., et al. Cell biology of IL-7, a key lymphotrophin. Cytokine Growth Factor Rev 2005, 16:513-533.
44. Johnson S.E., Shah N., Bajer A.A., LeBien T.W. IL-7 activates the phosphatidylinositol 3-kinase/AKT pathway in normal human thymocytes but not normal human B cell precursors. J Immunol 2008, 180:8109-8117.
45. Jotta P.Y., Ganazza M.A., Silva A., Viana M.B., da Silva M.J., Zambaldi L.J., et al. Negative prognostic impact of PTEN mutation in pediatric T-cell acute lymphoblastic leukemia. Leukemia 2010, 24:239-242.
46. Kalender Atak Z., De Keersmaecker K., Gianfelici V., Geerdens E., Vandepoel R., Pauwels D., et al. High accuracy mutation detection in leukemia on a selected panel of cancer genes. PLoS One 2012, 7:e38463.
47. Karawajew L., Ruppert V., Wuchter C., Kosser A., Schrappe M., Dorken B., et al. Inhibition of in vitro spontaneous apoptosis by IL-7 correlates with bcl-2 up-regulation, cortical/mature immunophenotype, and better early cytoreduction of childhood T-cell acute lymphoblastic leukemia. Blood 2000, 96:297-306.
48. Khaled A.R., Durum S.K. Lymphocide: cytokines and the control of lymphoid homeostasis. Nat Rev Immunol 2002, 2:817-830.
49. Khaled A.R., Durum S.K. Death and Baxes: mechanisms of lymphotrophic cytokines. Immunol Rev 2003, 193:48-57.
50. Khaled A.R., Li W.Q., Huang J., Fry T.J., Khaled A.S., Mackall C.L., et al. Bax deficiency partially corrects interleukin-7 receptor alpha deficiency. Immunity 2002, 17:561-573.
51. Kibe R., Zhang S., Guo D., Marrero L., Tsien F., Rodriguez P., et al. IL-7Ralpha deficiency in p53null mice exacerbates thymocyte telomere erosion and lymphomagenesis. Cell Death Differ 2012, 19:1139-1151.
52. Kittipatarin C., Khaled A.R. Interlinking interleukin-7. Cytokine 2007, 39:75-83.
53. Komschlies K.L., Gregorio T.A., Gruys M.E., Back T.C., Faltynek C.R., Wiltrout R.H. Administration of recombinant human IL-7 to mice alters the composition of B-lineage cells and T cell subsets, enhances T cell function, and induces regression of established metastases. J Immunol 1994, 152:5776-5784.
54. Lali F.V., Crawley J., McCulloch D.A., Foxwell B.M. A late, prolonged activation of the phosphatidylinositol 3-kinase pathway is required for T cell proliferation. J Immunol 2004, 172:3527-3534.
55. Laouar Y., Crispe I.N., Flavell R.A. Overexpression of IL-7R alpha provides a competitive advantage during early T-cell development. Blood 2004, 103:1985-1994.
56. Lee L.F., Logronio K., Tu G.H., Zhai W., Ni I., Mei L., et al. Anti-IL-7 receptor-alpha reverses established type 1 diabetes in nonobese diabetic mice by modulating effector T-cell function. Proc Natl Acad Sci U S A 2012, 109:12674-12679.
57. Lenz D.C., Kurz S.K., Lemmens E., Schoenberger S.P., Sprent J., Oldstone M.B., et al. IL-7 regulates basal homeostatic proliferation of antiviral CD4+T cell memory. Proc Natl Acad Sci U S A 2004, 101:9357-9362.
58. Li X., von Boehmer H. Notch Signaling in T-Cell Development and T-ALL. ISRN Hematol 2011, 921706.
59. Long B.W., Witte P.L., Abraham G.N., Gregory S.A., Plate J.M. Apoptosis and interleukin 7 gene expression in chronic B-lymphocytic leukemia cells. Proc Natl Acad Sci U S A 1995, 92:1416-1420.
60. Mackall C.L., Fleisher T.A., Brown M.R., Andrich M.P., Chen C.C., Feuerstein I.M., et al. Distinctions between CD8+ and CD4+ T-cell regenerative pathways result in prolonged T-cell subset imbalance after intensive chemotherapy. Blood 1997, 89:3700-3707.
61. Mackall C.L., Fleisher T.A., Brown M.R., Magrath I.T., Shad A.T., Horowitz M.E., et al. Lymphocyte depletion during treatment with intensive chemotherapy for cancer. Blood 1994, 84:2221-2228.
62. Mackall C.L., Fry T.J., Gress R.E. Harnessing the biology of IL-7 for therapeutic application. Nat Rev Immunol 2011, 11:330-342.
63. Makrynikola V., Kabral A., Bradstock K. Effects of interleukin 7 on the growth of clonogenic cells in T-cell acute lymphoblastic leukaemia. Leukemia Res 1991, 15:879-882.
64. Maser R.S., Choudhury B., Campbell P.J., Feng B., Wong K.K., Protopopov A., et al. Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers. Nature 2007, 447:966-971.
65. Masuda M., Motoji T., Oshimi K., Mizoguchi H. Effects of interleukin-7 on proliferation of hematopoietic malignant cells. Exp Hematol 1990, 18:965-967.
66. Mazzucchelli R., Durum S.K. Interleukin-7 receptor expression: intelligent design. Nat Rev Immunol 2007, 7:144-154.
67. Mazzucchelli R.I., Riva A., Durum S.K. The human IL-7 receptor gene: deletions, polymorphisms and mutations. Semin Immunol 2012, 24:225-230.
68. Mazzucchelli R.I., Warming S., Lawrence S.M., Ishii M., Abshari M., Washington A.V., et al. Visualization and identification of IL-7 producing cells in reporter mice. PloS ONE 2009, 4:e7637.
69. McElroy C.A., Holland P.J., Zhao P., Lim J.M., Wells L., Eisenstein E., et al. Structural reorganization of the interleukin-7 signaling complex. Proc Natl Acad Sci U S A 2012, 109:2503-2508.
70. Moller P., Sun Y., Dorbic T., Alijagic S., Makki A., Jurgovsky K., et al. Vaccination with IL-7 gene-modified autologous melanoma cells can enhance the anti-melanoma lytic activity in peripheral blood of patients with a good clinical performance status: a clinical phase I study. Br J Cancer 1998, 77:1907-1916.
71. Morrissey P.J., Conlon P., Braddy S., Williams D.E., Namen A.E., Mochizuki D.Y. Administration of IL-7 to mice with cyclophosphamide-induced lymphopenia accelerates lymphocyte repopulation. J Immunol 1991, 146:1547-1552.
72. Namen A.E., Schmierer A.E., March C.J., Overell R.W., Park L.S., Urdal D.L., et al. B cell precursor growth-promoting activity. Purification and characterization of a growth factor active on lymphocyte precursors. J Exp Med 1988, 167:988-1002.
73. Noguchi M., Yi H., Rosenblatt H.M., Filipovich A.H., Adelstein S., Modi W.S., et al. Interleukin-2 receptor gamma chain mutation results in X-linked severe combined immunodeficiency in humans. Cell 1993, 73:147-157.
74. Osborne L.C., Duthie K.A., Seo J.H., Gascoyne R.D., Abraham N. Selective ablation of the YxxM motif of IL-7Ralpha suppresses lymphomagenesis but maintains lymphocyte development. Oncogene 2010, 29:3854-3864.
75. Ouyang W., Beckett O., Flavell R.A., Li M.O. An essential role of the Forkhead-box transcription factor Foxo1 in control of T cell homeostasis and tolerance. Immunity 2009, 30:358-371.
76. Pallard C., Stegmann A.P., van Kleffens T., Smart F., Venkitaraman A., Spits H. Distinct roles of the phosphatidylinositol 3-kinase and STAT5 pathways in IL-7-mediated development of human thymocyte precursors. Immunity 1999, 10:525-535.
77. Park J.H., Adoro S., Guinter T., Erman B., Alag A.S., Catalfamo M., et al. Signaling by intrathymic cytokines, not T cell antigen receptors, specifies CD8 lineage choice and promotes the differentiation of cytotoxic-lineage T cells. Nat Immunol 2010, 11:257-264.
78. Park J.H., Yu Q., Erman B., Appelbaum J.S., Montoya-Durango D., Grimes H.L., et al. Suppression of IL7Ralpha transcription by IL-7 and other prosurvival cytokines: a novel mechanism for maximizing IL-7-dependent T cell survival. Immunity 2004, 21:289-302.
79. Pellegrini M., Bouillet P., Robati M., Belz G.T., Davey G.M., Strasser A. Loss of Bim increases T cell production and function in interleukin 7 receptor-deficient mice. J Exp Med 2004, 200:1189-1195.
80. Pellegrini M., Calzascia T., Toe J.G., Preston S.P., Lin A.E., Elford A.R., et al. IL-7 engages multiple mechanisms to overcome chronic viral infection and limit organ pathology. Cell 2011, 144:601-613.
81. Peschon J.J., Morrissey P.J., Grabstein K.H., Ramsdell F.J., Maraskovsky E., Gliniak B.C., et al. Early lymphocyte expansion is severely impaired in interleukin 7 receptor-deficient mice. J Exp Med 1994, 180:1955-1960.
82. Porcu M., Kleppe M., Gianfelici V., Geerdens E., De Keersmaecker K., Tartaglia M., et al. Mutation of the receptor tyrosine phosphatase PTPRC (CD45) in T-cell acute lymphoblastic leukemia. Blood 2012, 119:4476-4479.
83. Prlic M., Lefrancois L., Jameson S.C. Multiple choices: regulation of memory CD8 T cell generation and homeostasis by interleukin (IL)-7 and IL-15. J Exp Med 2002, 195:F49-F52.
84. Puel A., Ziegler S.F., Buckley R.H., Leonard W.J. Defective IL7R expression in T(-)B(+)NK(+) severe combined immunodeficiency. Nat Genet 1998, 20:394-397.
85. Radtke S., Haan S., Jorissen A., Hermanns H.M., Diefenbach S., Smyczek T., et al. The Jak1 SH2 domain does not fulfill a classical SH2 function in Jak/STAT signaling but plays a structural role for receptor interaction and up-regulation of receptor surface expression. J Biol Chem 2005, 280:25760-25768.
86. Ramanathan S., Gagnon J., Leblanc C., Rottapel R., Ilangumaran S. Suppressor of cytokine signaling 1 stringently regulates distinct functions of IL-7 and IL-15 in vivo during T lymphocyte development and homeostasis. J Immunol 2006, 176:4029-4041.
87. Rathmell J.C., Farkash E.A., Gao W., Thompson C.B. IL-7 enhances the survival and maintains the size of naive T cells. J Immunol 2001, 167:6869-6876.
88. Remke M., Pfister S., Kox C., Toedt G., Becker N., Benner A., et al. High-resolution genomic profiling of childhood T-ALL reveals frequent copy-number alterations affecting the TGF-beta and PI3K-AKT pathways and deletions at 6q15-16.1 as a genomic marker for unfavorable early treatment response. Blood 2009, 114:1053-1062.
89. Repass J.F., Laurent M.N., Carter C., Reizis B., Bedford M.T., Cardenas K., et al. IL7-hCD25 and IL7-Cre BAC transgenic mouse lines: new tools for analysis of IL-7 expressing cells. Genesis 2009, 47:281-287.
90. Rich B.E., Campos-Torres J., Tepper R.I., Moreadith R.W., Leder P. Cutaneous lymphoproliferation and lymphomas in interleukin 7 transgenic mice. J Exp Med 1993, 177:305-316.
91. Ridder A., Skupjen P., Unterreitmeier S., Langosch D. Tryptophan supports interaction of transmembrane helices. J Mol Biol 2005, 354:894-902.
92. Rosenberg S.A., Sportes C., Ahmadzadeh M., Fry T.J., Ngo L.T., Schwarz S.L., et al. IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells. J Immunother 2006, 29:313-319.
93. Russ W.P., Engelman D.M. The GxxxG motif: a framework for transmembrane helix-helix association. J Mol Biol 2000, 296:911-919.
94. Sakata T., Iwagami S., Tsuruta Y., Teraoka H., Tatsumi Y., Kita Y., et al. Constitutive expression of interleukin-7 mRNA and production of IL-7 by a cloned murine thymic stromal cell line. J Leukoc Biol 1990, 48:205-212.
95. Sasson S.C., Smith S., Seddiki N., Zaunders J.J., Bryant A., Koelsch K.K., et al. IL-7 receptor is expressed on adult pre-B-cell acute lymphoblastic leukemia and other B-cell derived neoplasms and correlates with expression of proliferation and survival markers. Cytokine 2010, 50:58-68.
96. Schluns K.S., Kieper W.C., Jameson S.C., Lefrancois L. Interleukin-7 mediates the homeostasis of naive and memory CD8 T cells in vivo. Nat Immunol 2000, 1:426-432.
97. Scupoli M.T., Perbellini O., Krampera M., Vinante F., Cioffi F., Pizzolo G. Interleukin 7 requirement for survival of T-cell acute lymphoblastic leukemia and human thymocytes on bone marrow stroma. Haematologica 2007, 92:264-266.
98. Scupoli M.T., Vinante F., Krampera M., Vincenzi C., Nadali G., Zampieri F., et al. Thymic epithelial cells promote survival of human T-cell acute lymphoblastic leukemia blasts: the role of interleukin-7. Haematologica 2003, 88:1229-1237.
99. Seddon B., Tomlinson P., Zamoyska R. Interleukin 7 and T cell receptor signals regulate homeostasis of CD4 memory cells. Nat Immunol 2003, 4:680-686.
100. Sereti I., Dunham R.M., Spritzler J., Aga E., Proschan M.A., Medvik K., et al. IL-7 administration drives T cell-cycle entry and expansion in HIV-1 infection. Blood 2009, 113:6304-6314.
101. Shochat C., Tal N., Bandapalli O.R., Palmi C., Ganmore I., te Kronnie G., et al. Gain-of-function mutations in interleukin-7 receptor-alpha (IL7R) in childhood acute lymphoblastic leukemias. J Exp Med 2011, 208:901-908.
102. Silva A., Girio A., Cebola I., Santos C.I., Antunes F., Barata J.T. Intracellular reactive oxygen species are essential for PI3K/Akt/mTOR-dependent IL-7-mediated viability of T-cell acute lymphoblastic leukemia cells. Leukemia 2011, 25:960-967. Official Journal of the Leukemia Society of America, Leukemia Research Fund, UK.
103. Silva A., Laranjeira A.B., Martins L.R., Cardoso B.A., Demengeot J., Yunes J.A., et al. IL-7 contributes to the progression of human T-cell acute lymphoblastic leukemias. Cancer Res 2011, 71:4780-4789.
104. Silva A., Yunes J.A., Cardoso B.A., Martins L.R., Jotta P.Y., Abecasis M., et al. PTEN posttranslational inactivation and hyperactivation of the PI3K/Akt pathway sustain primary T cell leukemia viability. J Clin Invest 2008, 118:3762-3774.
105. Simioni C., Neri L.M., Tabellini G., Ricci F., Bressanin D., Chiarini F., et al. Cytotoxic activity of the novel Akt inhibitor, MK-2206, in T-cell acute lymphoblastic leukemia. Leukemia 2012, Official Journal of the Leukemia Society of America, Leukemia Research Fund, UK.
106. Sinclair C., Saini M., van der Loeff I.S., Sakaguchi S., Seddon B. The long-term survival potential of mature T lymphocytes is programmed during development in the thymus. Sci Sigal 2011, 4:ra77.
107. Soares M.V., Borthwick N.J., Maini M.K., Janossy G., Salmon M., Akbar A.N. IL-7-dependent extrathymic expansion of CD45RA+ T cells enables preservation of a naive repertoire. J Immunol 1998, 161:5909-5917.
108. Sportes C., Babb R.R., Krumlauf M.C., Hakim F.T., Steinberg S.M., Chow C.K., et al. Phase I study of recombinant human interleukin-7 administration in subjects with refractory malignancy. Clin Cancer Res 2010, 16:727-735.
109. Sportes C., Hakim F.T., Memon S.A., Zhang H., Chua K.S., Brown M.R., et al. Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets. J Exp Med 2008, 205:1701-1714.
110. Swainson L., Kinet S., Mongellaz C., Sourisseau M., Henriques T., Taylor N. IL-7-induced proliferation of recent thymic emigrants requires activation of the PI3K pathway. Blood 2007, 109:1034-1042.
111. Tokoyoda K., Egawa T., Sugiyama T., Choi B.I., Nagasawa T. Cellular niches controlling B lymphocyte behavior within bone marrow during development. Immunity 2004, 20:707-718.
112. Touw I., Pouwels K., van Agthoven T., van Gurp R., Budel L., Hoogerbrugge H., et al. Interleukin-7 is a growth factor of precursor B and T acute lymphoblastic leukemia. Blood 1990, 75:2097-2101.
113. Trigueros C., Hozumi K., Silva-Santos B., Bruno L., Hayday A.C., Owen M.J., et al. Pre-TCR signaling regulates IL-7 receptor alpha expression promoting thymocyte survival at the transition from the double-negative to double-positive stage. Eur J Immunol 2003, 33:1968-1977.
114. Tussiwand R., Engdahl C., Gehre N., Bosco N., Ceredig R., Rolink A.G. The preTCR-dependent DN3 to DP transition requires Notch signaling, is improved by CXCL12 signaling and is inhibited by IL-7 signaling. Eur J Immunol 2011, 41:3371-3380.
115. von Freeden-Jeffry U., Solvason N., Howard M., Murray R. The earliest T lineage-committed cells depend on IL-7 for Bcl-2 expression and normal cell cycle progression. Immunity 1997, 7:147-154.
116. von Freeden-Jeffry U., Vieira P., Lucian L.A., McNeil T., Burdach S.E., Murray R. Lymphopenia in interleukin (IL)-7 gene-deleted mice identifies IL-7 as a nonredundant cytokine. J Exp Med 1995, 181:1519-1526.
117. Walters D.K., Mercher T., Gu T.L., O'Hare T., Tyner J.W., Loriaux M., et al. Activating alleles of JAK3 in acute megakaryoblastic leukemia. Cancer Cell 2006, 10:65-75.
118. Weng A.P., Ferrando A.A., Lee W., Morris JPt, Silverman L.B., Sanchez-Irizarry C., et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 2004, 306:269-271.
119. Wiles M.V., Ruiz P., Imhof B.A. Interleukin-7 expression during mouse thymus development. Eur J Immunol 1992, 22:1037-1042.
120. Wofford J.A., Wieman H.L., Jacobs S.R., Zhao Y., Rathmell J.C. IL-7 promotes Glut1 trafficking and glucose uptake via STAT5-mediated activation of Akt to support T-cell survival. Blood 2008, 111:2101-2111.
121. Ye S.K., Agata Y., Lee H.C., Kurooka H., Kitamura T., Shimizu A., et al. The IL-7 receptor controls the accessibility of the TCRgamma locus by Stat5 and histone acetylation. Immunity 2001, 15:813-823.
122. Zenatti P.P., Ribeiro D., Li W., Zuurbier L., Silva M.C., Paganin M., et al. Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia. Nat Genet 2011, 43:932-939.
123. Zhang J., Ding L., Holmfeldt L., Wu G., Heatley S.L., Payne-Turner D., et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature 2012, 481:157-163.
124. Zhou Y.J., Chen M., Cusack N.A., Kimmel L.H., Magnuson K.S., Boyd J.G., et al. Unexpected effects of FERM domain mutations on catalytic activity of Jak3: structural implication for Janus kinases. Mol Cell 2001, 8:959-969.